About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus

Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus

NCT00057317·117 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Hoffmann-La Roche

Age

35–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Age 35 to 75
Type 2 diabetes for longer than 3 months
HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening
FPG (fasting plasma glucose) greater than 126 mg/dL at screening
BMI (body mass index) less than 40 kg/square meter

You may not be if

Type I diabetes
Type 2 diabetes patients currently treated with insulin
Type 2 diabetes patients currently or previously treated with Actos, Avandia or Rezulin
FPG (fasting plasma glucose) greater than 270 mg/dL at baseline
Impaired liver or kidney function
Triglycerides greater than 600 mg/dL
Uncontrolled hypertension
Pregnant or lactating women
Women not using adequate contraception

The record

StatusCompleted

PhasePhase 2

Taking part—

StartedDec 2001

UpdatedAug 24, 2016

Conditions

Where117

Huntsville, Alabama, United States
Mesa, Arizona, United States
Scottsdale, Arizona, United States